Received Jun 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | KR75K | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 27LR2 | — |
A 52 years old female patient received a dose of Boostrix and a dose of Shingrix after a temperature excursion.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 52-year-old female patient who received Herpes zoster (Shingrix) (batch number 27LR2, expiry date 25-MAR-2027) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) (batch number KR75K, expiry date 27-AUG-2027) for prophylaxis. On an unknown date, the patient received Shingrix and Boostrix. On an unknown date, an unknown time after receiving Shingrix and Boostrix, the patient experienced incorrect storage of drug (Verbatim: A 52 years old female patient received a dose of Boostrix and a dose of Shingrix after a temperature excursion.). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-JUN-2025 The office manager called to ask about the stability of Boostrix and Shingrix, after a temperature excursion of minus 14 degree C for 24 hours. No prior excursion. Office Manager mentioned that they administered 1 dose of Boostrix and 1 dose of Shingrix to a 52 years old female patient after this temperature excursion, which led to Incorrect storage of drug.